CA2612315A1 - Dosage regimen for prasugrel - Google Patents
Dosage regimen for prasugrel Download PDFInfo
- Publication number
- CA2612315A1 CA2612315A1 CA002612315A CA2612315A CA2612315A1 CA 2612315 A1 CA2612315 A1 CA 2612315A1 CA 002612315 A CA002612315 A CA 002612315A CA 2612315 A CA2612315 A CA 2612315A CA 2612315 A1 CA2612315 A1 CA 2612315A1
- Authority
- CA
- Canada
- Prior art keywords
- prasugrel
- compound
- dose
- formula
- equivalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 title claims abstract description 96
- 229960004197 prasugrel Drugs 0.000 title claims abstract description 93
- 239000005465 B01AC22 - Prasugrel Substances 0.000 title claims abstract description 86
- 238000012423 maintenance Methods 0.000 claims abstract description 45
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 208000019553 vascular disease Diseases 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 37
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 20
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 20
- 208000007536 Thrombosis Diseases 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000001435 Thromboembolism Diseases 0.000 claims description 9
- 238000013146 percutaneous coronary intervention Methods 0.000 claims description 9
- 208000005189 Embolism Diseases 0.000 claims description 8
- JALHGCPDPSNJNY-UHFFFAOYSA-N [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4h-thieno[3,2-c]pyridin-2-yl] acetate;hydron;chloride Chemical compound Cl.C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 JALHGCPDPSNJNY-UHFFFAOYSA-N 0.000 claims description 7
- 229960004947 prasugrel hydrochloride Drugs 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 150000003840 hydrochlorides Chemical class 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 28
- 229960003009 clopidogrel Drugs 0.000 description 28
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 27
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 15
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 14
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000007792 addition Methods 0.000 description 8
- 230000000977 initiatory effect Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 229940125670 thienopyridine Drugs 0.000 description 6
- 239000002175 thienopyridine Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 229940127218 antiplatelet drug Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 230000010102 embolization Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 4
- 208000032109 Transient ischaemic attack Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229940047170 clopidogrel 300 mg Drugs 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000013152 interventional procedure Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 201000010875 transient cerebral ischemia Diseases 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002329 Aneurysm Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000007214 atherothrombosis Effects 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000007631 vascular surgery Methods 0.000 description 2
- BFCDFTHTSVTWOG-PXNSSMCTSA-N (1r,2s)-2-(octylamino)-1-(4-propan-2-ylsulfanylphenyl)propan-1-ol Chemical compound CCCCCCCCN[C@@H](C)[C@H](O)C1=CC=C(SC(C)C)C=C1 BFCDFTHTSVTWOG-PXNSSMCTSA-N 0.000 description 1
- WJFYLCXWEXZNHU-UHFFFAOYSA-N 2,3,3a,4-tetrahydrothieno[3,2-b]pyridine Chemical class N1C=CC=C2SCCC21 WJFYLCXWEXZNHU-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000009447 Cardiac Edema Diseases 0.000 description 1
- 208000006017 Cardiac Tamponade Diseases 0.000 description 1
- 206010007513 Cardiac aneurysm Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000035211 Heart Murmurs Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101100001347 Mus musculus Akt1s1 gene Proteins 0.000 description 1
- 208000013544 Platelet disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229940098003 aspirin 325 mg Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940066015 clopidogrel 75 mg Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- -1 maleate salt Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229940101750 prasugrel 10 mg Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69174005P | 2005-06-17 | 2005-06-17 | |
| US60/691,740 | 2005-06-17 | ||
| PCT/US2006/023006 WO2006138317A2 (en) | 2005-06-17 | 2006-06-13 | Dosage regimen for prasugrel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2612315A1 true CA2612315A1 (en) | 2006-12-28 |
Family
ID=37571073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002612315A Abandoned CA2612315A1 (en) | 2005-06-17 | 2006-06-13 | Dosage regimen for prasugrel |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20090156632A1 (enExample) |
| EP (1) | EP1893205A4 (enExample) |
| JP (1) | JP2008543853A (enExample) |
| KR (1) | KR20080016647A (enExample) |
| CN (1) | CN101198329A (enExample) |
| AU (1) | AU2006259538A1 (enExample) |
| BR (1) | BRPI0612624A2 (enExample) |
| CA (1) | CA2612315A1 (enExample) |
| EA (1) | EA200800075A1 (enExample) |
| EC (1) | ECSP078014A (enExample) |
| GT (1) | GT200600263A (enExample) |
| IL (1) | IL187486A0 (enExample) |
| MA (1) | MA29722B1 (enExample) |
| MX (1) | MX2007015430A (enExample) |
| NO (1) | NO20080244L (enExample) |
| TN (1) | TNSN07474A1 (enExample) |
| WO (1) | WO2006138317A2 (enExample) |
| ZA (1) | ZA200710769B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101647842B1 (ko) * | 2006-12-07 | 2016-08-11 | 다이이찌 산쿄 가부시키가이샤 | 저장 안정성이 개선된 의약 조성물 |
| EP2100610A4 (en) | 2006-12-07 | 2009-12-02 | Daiichi Sankyo Co Ltd | PHARMACEUTICAL COMPOSITION WITH LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE |
| RU2470636C2 (ru) | 2007-04-27 | 2012-12-27 | Сайдекс Фамэсьютиклз, Инк. | Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты) |
| ES2769949T3 (es) | 2009-05-13 | 2020-06-29 | Cydex Pharmaceuticals Inc | Composiciones farmacéuticas que comprenden prasugrel y derivados de ciclodextrina y métodos de preparación y uso de las mismas |
| US10376532B2 (en) * | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| TR201006802A1 (tr) * | 2010-08-17 | 2012-03-21 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Prasugrelin oral yolla dağılan formülasyonları. |
| EP2409685A3 (en) | 2010-07-19 | 2012-02-01 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally-disintegrating formulations of prasugrel |
| WO2016203018A1 (en) | 2015-06-19 | 2016-12-22 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions of prasugrel hydrobromide |
| WO2018167447A1 (en) * | 2017-03-14 | 2018-09-20 | University Of Sheffield | Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI101150B (fi) * | 1991-09-09 | 1998-04-30 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi |
| US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
| US6544981B2 (en) * | 2000-06-09 | 2003-04-08 | Bristol-Myers Squibb Company | Lactam inhibitors of factor Xa and method |
| JP4001199B2 (ja) * | 2000-07-06 | 2007-10-31 | 第一三共株式会社 | ヒドロピリジン誘導体酸付加塩 |
| KR20030014294A (ko) * | 2000-07-06 | 2003-02-15 | 상꾜 가부시키가이샤 | 히드로피리딘 유도체 산부가염 |
| PL206138B1 (pl) * | 2000-12-25 | 2010-07-30 | Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited | Kompozycja farmaceutyczna zawierająca aspirynę oraz zestaw i zastosowanie składników kompozycji |
| JP4874482B2 (ja) * | 2000-12-25 | 2012-02-15 | 第一三共株式会社 | アスピリンを含有する医薬組成物 |
| WO2004098713A2 (en) * | 2003-05-05 | 2004-11-18 | Eli Lilly And Company | Treating cardiovascular diseases with a compound of formula (i) (cs 747 - prasugrel; rn 150322-43-4) |
-
2006
- 2006-06-13 BR BRPI0612624A patent/BRPI0612624A2/pt not_active IP Right Cessation
- 2006-06-13 MX MX2007015430A patent/MX2007015430A/es unknown
- 2006-06-13 AU AU2006259538A patent/AU2006259538A1/en not_active Abandoned
- 2006-06-13 US US11/916,817 patent/US20090156632A1/en not_active Abandoned
- 2006-06-13 CN CNA2006800217943A patent/CN101198329A/zh active Pending
- 2006-06-13 JP JP2008517022A patent/JP2008543853A/ja active Pending
- 2006-06-13 CA CA002612315A patent/CA2612315A1/en not_active Abandoned
- 2006-06-13 WO PCT/US2006/023006 patent/WO2006138317A2/en not_active Ceased
- 2006-06-13 EP EP06773053A patent/EP1893205A4/en not_active Withdrawn
- 2006-06-13 KR KR1020077029366A patent/KR20080016647A/ko not_active Ceased
- 2006-06-13 EA EA200800075A patent/EA200800075A1/ru unknown
- 2006-06-16 GT GT200600263A patent/GT200600263A/es unknown
-
2007
- 2007-11-19 IL IL187486A patent/IL187486A0/en unknown
- 2007-12-11 ZA ZA200710769A patent/ZA200710769B/xx unknown
- 2007-12-14 TN TNP2007000474A patent/TNSN07474A1/en unknown
- 2007-12-14 EC EC2007008014A patent/ECSP078014A/es unknown
-
2008
- 2008-01-14 NO NO20080244A patent/NO20080244L/no not_active Application Discontinuation
- 2008-01-16 MA MA30577A patent/MA29722B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1893205A4 (en) | 2010-06-30 |
| MA29722B1 (fr) | 2008-09-01 |
| TNSN07474A1 (en) | 2009-03-17 |
| EA200800075A1 (ru) | 2008-04-28 |
| NO20080244L (no) | 2008-01-14 |
| JP2008543853A (ja) | 2008-12-04 |
| ECSP078014A (es) | 2008-01-23 |
| AU2006259538A1 (en) | 2006-12-28 |
| MX2007015430A (es) | 2008-02-21 |
| ZA200710769B (en) | 2009-09-30 |
| KR20080016647A (ko) | 2008-02-21 |
| WO2006138317A3 (en) | 2007-05-03 |
| WO2006138317A2 (en) | 2006-12-28 |
| EP1893205A2 (en) | 2008-03-05 |
| US20090156632A1 (en) | 2009-06-18 |
| GT200600263A (es) | 2007-02-23 |
| IL187486A0 (en) | 2008-06-05 |
| BRPI0612624A2 (pt) | 2016-11-29 |
| CN101198329A (zh) | 2008-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8569325B2 (en) | Method of treatment with coadministration of aspirin and prasugrel | |
| AU2006258102B2 (en) | Formulation of a thienopyridine platelet aggregation inhibitor | |
| EP3687505A1 (en) | Niraparib formulations | |
| US20250099466A1 (en) | Milvexian for prevention and treatment of thromboembolic disorders | |
| KR101764785B1 (ko) | 약제학적 복합제제 | |
| US20090156632A1 (en) | Dosage regimen for prasugrel | |
| CN112402432A (zh) | 治疗或预防具有心肌梗塞病史的患者的动脉粥样硬化血栓形成事件的方法 | |
| Turpie | Warfarin replacements: mechanisms underlying emerging agents | |
| Heidbuchel et al. | Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice | |
| WO2011052500A1 (ja) | ワックス安定製剤 | |
| WO2011052499A1 (ja) | 貯蔵安定性が改善された医薬組成物 | |
| HK40045857A (en) | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction | |
| HK40045855A (en) | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction | |
| HK1056118B (en) | Medicinal compositions containing aspirin | |
| HK1116422B (en) | Formulation of a thienopyridine platelet aggregation inhibitor | |
| HK40045856A (en) | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction | |
| Vet—QC09CA02 | Eprosartan Mesilate (BANM, rINNM) | |
| HK1248580A1 (en) | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction | |
| NZ730307B2 (en) | Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation | |
| NZ730307A (en) | Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |